Resumen

Elegibilidad

Detalles del diseño

Brazos e Intervenciones

Medidas de resultado

Sitios del ensayo

Fuente: NCT04207437

Reclutamiento

Daily Hand-Held Vibration Therapy

Intervencionista

Fase no especificada

Indiana University Melvin & Bren Simon Cancer Center

The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands. The investigators hypothesize that daily vibration therapy can reduce the severity of patient's CIPN in their hands and improve CIPN-related quality of life. The hope is that results from this study will provide early data on the feasibility, efficacy, and most importantly, safety, of daily 3-minute hand-held vibration therapy needed to justify future clinical trials examining vibration therapy as a potential option for treating CIPN in the future.

Categoría de tratamiento

Dispositivo

Erforderliche Mutationen

Ninguna

Ensayo iniciado

2021-12-06

Última actualización por el patrocinador

2025-07-28

Finalización estimada

2025-12-01

Elegibilidad

Criterios de inclusión

1. 18 years or older at enrollment

2. Able to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization

3. Have completed chemotherapy ≥ 60 days prior to enrollment

4. Were exposed to neurotoxic chemotherapy with one or more of the following agents in the following doses: Paclitaxel (cumulative dose: ≥ 300 mg/m2) Docetaxel (cumulative dose: ≥ 100 mg/m2) Nab-paclitaxel (cumulative dose: ≥ 750 mg/m2) Oxaliplatin (cumulative dose: ≥ 510 mg/m2) Carboplatin (cumulative dose: ≥ 600 mg/m2) Cisplatin (cumulative dose: ≥ 200 mg/m2) Vincristine (cumulative dose: ≥ 4 mg/m2) Bortezomib (cumulative dose: ≥ 16 mg/m)

5. Continue to display evidence of sensory CIPN in the hands rated at a Grade ≥ 2 according the National Cancer Institute's Common Toxicity Criteria-Adverse Events (NCI-CTC-AE, Version 5.0) Scale ≥ 60 days post-chemotherapy

6. If solid tumor cancer, must have non-metastatic cancer

7. Agree to return to clinic for required study related measurements at specified intervals

Criterios de exclusión

1. Have pre-existing neuropathy affecting the hands not related to chemotherapy (e.g., carpal tunnel syndrome, nerve compression, etc.)

2. Known diagnosis of diabetes mellitus.

3. Known contraindications for vibration therapy to hands, including deep venous thrombosis of the upper extremity or ongoing skin infection.

4. Will be receiving concurrent radiation of the upper-extremity

¿Cree usted que este ensayo clínico se muestra por error?

Detalles del diseño

AsignaciónN/A

Modelo de intervenciónSingle Group Assignment

EnmascaramientoNone (Open Label)

Número a inscribir16

Brazos e Intervenciones

Brazos

Intervenciones

Tipo: Experimental

Descripción: Patients will hold a hand held vibrating device for 3 minutes on each hand daily for 4 weeks.

Intervenciones:

Vibration therapy

Medidas de resultado

Medidas de resultado primarias

Feasibility of recruitment- percentage of patients who agree to participate in the study after screeningrecruitment period (up to 1 year after study starts)

Feasibility of compliance- percentage of vibration therapy sessions completed4 weeks

Compliance with the daily vibration therapy sessions will be evaluated using data from a Daily Compliance Form Researchers will calculate the percentage of sessions that were completed calculated for each participant, on each hand. Participant compliance with the intervention will be considered acceptable if participants complete ≥ 80% of the sessions they were assigned.

Acceptability of Intervention- percentage of patients who answer agree on acceptability form4 weeks

percentage of participants who answer "somewhat agree," "agree," or "strongly agree" on the intervention acceptability form

Change in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy twenty-item scale (CIPN20) scoresbaseline, week 1, week 2, week 3, week 4

CIPN 20 questionnaire scores will be compared to baseline weekly to identify an increase of 30% during the intervention period. The CIPN scores range from 20 to 80 with 80 being consistent with the most severe neuropathy symptoms

Medidas de resultado secundarias

Change in CIPN Severity via the CIPN20 questionnaire scoresbaseline, weeks 1, 2, 3, and 4, 5, 6, 7, and week 8

Summary statistics for the weekly CIPN-20 (n, mean, standard deviation, median, minimum, maximum)

Change in CIPN related Quality of Life via the Chemotherapy Induced Peripheral Neuropathy Quality of Life Scalebaseline, week 4, week 8

Descriptive statistics (frequency and percentage for each category, mean and standard deviation of scores assigned to each category (range: 0-7)) will be used to describe the CIPN-related QOL participants have on each of the three categories related to quality of life

¿Interesado en participar?

Obtenga más información sobre este ensayo y si puede ser elegible para participar.

Guardar ensayo

Compartir ensayo por correo electrónico

Descargar ensayo

¿Cree usted que este ensayo clínico se muestra por error?

Reportar ensayo

Descargar ensayo

Sitios del ensayo

Este estudio tiene 3 sitios de ensayo

Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, US

Reclutando

Indianapolis, Indiana, 46202 US

Indiana University Melvin & Bren Simon Cancer Center

Reclutando

Indianapolis, Indiana, 46202 US

IU Health Joe & Shelly Schwarz Cancer Center

Reclutando

Avon, Indiana, 46123 US

Indiana University Health West

Loading Maps...